Company / Shareholders' Equity
PharmaCyte Biotech, Inc. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$27.6M
FY2025
5-year range
$5.1M / $89.9M
FY2021-FY2025
Trend
-62.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Shareholders' Equity has fluctuated over the past 10 years, ranging from $5M in FY2020 to $90M in FY2023.
Based on SEC 10-K filings.
$28M in FY2025 with a 5-year CAGR of +40.6%.
Declined from $90M to $28M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +60.6%
- 5-Year CAGR
- +40.6%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +40.6%, indicating consistent growth.
- In FY2025, shareholders' equity decreased 62.0% year-over-year.
- Peak shareholders' equity was recorded in FY2023.
- Lowest shareholders' equity in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score 0.20 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $27.6M | -62.0% |
| FY2024 | $72.7M | -19.2% |
| FY2023 | $89.9M | +1246.2% |
| FY2022 | $6.7M | +31.3% |
| FY2021 | $5.1M | +1.0% |
| FY2020 | $5.0M | -12.6% |
| FY2019 | $5.8M | -28.7% |
| FY2018 | $8.1M | +24.0% |
| FY2017 | $6.5M | -16.1% |
| FY2016 | $7.8M | +441.1% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026